A Gastrinoma is a tumor that is typically found in the pancreas and duodenum and is the hallmark of a relatively rare gastrointestinal disorder known as Zollinger-Ellison Syndrome (ZES). Gastrinomas secrete large quantities of the hormone gastrin which triggers gastric acid production that can then produce ulcers. ZES constitutes 0.1% or more of cases of peptic ulcer disease. A gastrinoma can be malignant or benign and, although rare, gastrinomas are the most common pancreatic islet cell tumors.

The definitive diagnosis of a gastrinoma is sometimes difficult due to the similarities in symptoms with peptic ulcer disease including burning pain in the abdomen, diarrhea, nausea, vomiting, fatigue, weakness and weight loss. SecreFloTM administered intravenously stimulates the release of excessive amounts of gastrin into the bloodstream of patients with a gastrinoma. Normal subjects or patients with other peptic ulcer diseases experience only small changes in serum gastrin concentrations. Gastrinoma is strongly suspected in patients who show an increase in serum gastrin concentration of more than 110 pg per ml over basal gastrin levels on any post injection samples.

This increase in the level of serum gastrin is the basis for the use of SecreFloTM as a provocative agent in the evaluation of patients in whom gastrinoma is a diagnostic consideration.

Quick Reference Dosing:
For Stimulation of gastrin secretion to aid in the diagnosis of gastrinoma: 0.4mcg/kg body weight of SecreFloTM intravenous injection over 1 minute.

For more detailed information about SecreFloTM, please refer to the Full Prescribing Information